Lyell Immunopharma Inc (LYEL) Stock Price

17.68 ▲ +0.17 (+0.97%)
Open: 16.08 Vol: 38.34K Day's range: 16.08 - 18.19 Nov 10, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
LYEL Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 17.78▼ 17.79▼ 17.82▼ 17.11▲ 17.20▲
MA10 17.79▼ 17.83▼ 17.73▲ 16.86▲ 15.90▲
MA20 17.84▼ 17.67▲ 17.52▲ 17.10▲ 13.33▲
MA50 17.81▼ 17.33▲ 16.96▲ 15.42▲ 12.09▲
MA100 17.68▲ 17.05▲ 17.12▲ 12.92▲ 24.40▼
MA200 17.26▲ 17.24▲ 16.45▲ 11.73▲ 52.35▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.012▼ -0.018▼ 0.014▲ -0.078▼ 0.713▲
RSI 45.539▼ 54.133▲ 55.829▲ 57.629▲ 63.933▲
STOCH 34.859     45.509     77.116     52.645     72.727    
WILL %R -72.093     -52.212     -20.996▲ -31.944     -17.403▲
CCI -105.876▼ -9.990     55.587     48.730     74.964    
Latest Filters Detected On LYEL
▲ PSAR&MOM $LYEL PSAR Switch Up + Momentum Set Alert
▼ GAP $LYEL Open Gap Down %5 Set Alert
▼ GAP $LYEL Open Gap Down %3 Set Alert
▼ GAP $LYEL Open Gap Down %2 Set Alert
Lyell Immunopharma Inc News
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Monday, November 10, 2025 04:52 AM
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic ...
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and ...
Monday, November 03, 2025 07:15 AM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts ...
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the ...
Monday, November 03, 2025 05:00 AM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with ...
LYEL historical stock data
date open high low close volume
10/11/25 16.08 18.19 16.08 17.68 38,341
07/11/25 17.43 17.725 16.57 17.51 21,459
06/11/25 16.42 17.95 16.00 17.88 30,715
05/11/25 16.15 17.46 16.12 16.54 19,419
04/11/25 16.55 17.75 15.72 15.95 38,050
03/11/25 16.87 17.31 15.94 16.55 21,569
31/10/25 16.33 16.875 16.33 16.66 11,071
30/10/25 16.59 17.035 16.29 16.53 10,073
29/10/25 16.71 17.06 16.47 16.59 12,774
28/10/25 17.11 17.59 16.48 16.71 12,913
Quote Details
52wk Low:7.65
52wk High:23.20
Vol:38.34K
Avg Vol(3m):725.4K
1Y Chng:-3.17%
1M Chng:+8.87%
Add to Watch List
More Information
Index US Composite
Market Cap. 336.39M